Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ACTRN12625000892415) titled 'A First in Human, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of TT20 Administered Intravenously as Single Dose Infusions and Continuous Infusions in Healthy Adult Volunteers' on Aug. 18.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Type of endpoint: Safety
Primary Sponsor: Tellus Therapeutics
Condition:
Neonatal Brain Injury
Neonatal Brain Injury
Neurological - Other neurological disorders
Reproductive Health and Childbirth - Complications of newborn
Intervention:
TT-20 ...